The global Biological Indicators Market was valued at USD 572.3 million in 2025 and is projected to grow from USD 613.6 million in 2026 to USD 1,106.2 million by 2033, registering a CAGR of 8.8% from 2026 to 2033. The market is experiencing robust growth due to increasing emphasis on sterilization validation, infection prevention, regulatory compliance, and patient safety across healthcare, pharmaceutical, biotechnology, and medical device industries.

Biological indicators (BIs) are widely recognized as the gold standard for validating sterilization processes. These indicators contain highly resistant microorganisms that verify whether sterilization procedures effectively eliminate microbial contamination. As healthcare systems worldwide intensify efforts to reduce infection risks and improve quality assurance standards, demand for biological indicators continues to accelerate.

The market is also benefiting from advancements in rapid-readout technologies, automation systems, and growing adoption of sterilization monitoring practices in emerging economies. Increasing investments in healthcare infrastructure and pharmaceutical manufacturing are expected to further support market expansion during the forecast period.

Rising Hospital-Acquired Infections Driving Demand

One of the primary factors fueling growth in the biological indicators market is the increasing prevalence of hospital-acquired infections (HAIs), which continue to pose significant challenges to healthcare systems globally.

According to the World Health Organization's Global Report on Infection Prevention and Control 2024, a systematic review of nearly 400 studies estimated the global prevalence of HAIs at approximately 14% in 2023. Furthermore, a European point prevalence survey conducted across 28 EU/EEA countries and three Western Balkan territories during 2022/2023 reported an adjusted prevalence of 8% among patients with at least one HAI.

The growing burden of healthcare-associated infections is increasing the need for reliable sterilization validation solutions, making biological indicators an essential component of infection prevention strategies.

Download a free sample copy of the Biological Indicators Market report to understand detailed coverage and inclusions in the final report

Healthcare facilities are increasingly implementing stricter sterilization protocols to:

• Reduce infection transmission risks
• Improve patient safety outcomes
• Maintain regulatory compliance
• Strengthen quality assurance programs
• Validate sterilization effectiveness

As infection control remains a top priority for healthcare providers, biological indicators are expected to witness sustained demand globally.

Growing Surgical Volumes Supporting Market Expansion

The increasing number of surgical procedures performed worldwide is creating significant opportunities for biological indicator manufacturers.

Hospitals, ambulatory surgical centers, and specialty clinics are experiencing rising procedural volumes across multiple medical disciplines, including:

• General surgery
• Orthopedic procedures
• Cardiovascular interventions
• Cosmetic surgeries
• Organ transplantation
• Minimally invasive procedures

According to the 2024 Procedural Statistics Release, approximately 1,585,878 cosmetic surgeries were performed in 2024, representing a 1% increase compared to 2023. During the same period, reconstructive procedures increased by 2%.

The growing use of reusable surgical instruments, implantable devices, and endoscopic equipment requires continuous sterilization validation, driving the need for biological indicators to ensure patient safety and compliance with healthcare standards.

Emerging Trend: Rapid Readout Biological Indicators

A major trend transforming the biological indicators industry is the increasing adoption of rapid-readout technologies.

Traditional biological indicators often require extended incubation periods to confirm sterilization efficacy. However, healthcare facilities and pharmaceutical manufacturers are increasingly adopting rapid-readout biological indicators that provide faster results while maintaining high accuracy.

Benefits of rapid-readout systems include:

• Faster sterilization release decisions
• Reduced equipment downtime
• Improved operational efficiency
• Enhanced workflow management
• Greater compliance confidence

As healthcare organizations continue to prioritize efficiency and patient safety, rapid biological indicators are expected to gain significant market traction.

Key Market Trends & Insights

Self-Contained Biological Indicators Lead Product Segment

• By product, the self-contained segment held the largest revenue share in 2025.
• Self-contained biological indicators integrate the spore carrier and growth medium within a single unit.
• This design simplifies sterilization validation procedures and minimizes contamination risks.
• The segment's growth is driven by:
  • Ease of use
  • Improved reliability
  • Reduced handling requirements
  • Growing demand for rapid sterilization monitoring solutions

Healthcare facilities and pharmaceutical companies increasingly prefer self-contained systems due to their operational convenience and enhanced testing accuracy.

Steam Sterilization Maintains Market Leadership

• By method, the steam sterilization segment accounted for the largest revenue share in 2025.
• Steam sterilization remains the most widely used sterilization technique across healthcare and pharmaceutical environments.
• The method is recognized for its:
  • Proven effectiveness
  • Cost-efficiency
  • Safety profile
  • Ability to eliminate highly resistant microorganisms

Looking for more specific insights? Customize this report to suite your business needs

Applications include:

• Surgical instrument sterilization
• Laboratory glassware processing
• Pharmaceutical equipment sterilization
• Culture media preparation
• Central sterile supply departments (CSSDs)

The continued reliance on steam sterilization systems supports strong demand for corresponding biological indicators.

Hospitals & Clinics Dominate End-Use Demand

• By end use, the hospitals & clinics segment held the largest revenue share in 2025.
• Healthcare facilities perform large volumes of sterilization procedures daily to support patient care and surgical operations.
• Growing procedural complexity and infection prevention requirements continue to strengthen demand for biological indicators.
• Hospitals increasingly utilize biological indicators for:
  • Surgical instruments
  • Endoscopes
  • Implantable devices
  • Critical care equipment
  • Sterile processing validation

Strict compliance requirements and patient safety initiatives remain key factors supporting segment growth.

Regulatory Compliance Continues to Drive Adoption

Stringent regulatory requirements remain one of the strongest long-term drivers of the biological indicators market.

Global regulatory agencies and quality standards organizations require sterilization validation across healthcare and life sciences industries.

Examples include:

• U.S. FDA 21 CFR Part 820 Quality System Regulation
• ISO 11138 Biological Indicator Standards
• European Medicines Agency (EMA) sterilization requirements
• Good Manufacturing Practices (GMP) guidelines

Biological indicators are considered essential tools for demonstrating compliance with sterilization validation requirements and maintaining product safety standards.

As regulatory oversight continues to strengthen globally, demand for validated sterilization monitoring solutions is expected to increase further.

Regional Highlights

North America Leads Global Market

• North America accounted for 41.8% of global revenue in 2025.
• The region benefits from advanced healthcare infrastructure, stringent regulatory standards, and high adoption of infection control technologies.
• Strong pharmaceutical manufacturing activity and increasing surgical volumes continue to support market growth.
• Growing investments in healthcare quality improvement initiatives further reinforce regional leadership.

United States Remains the Largest Country Market

• The U.S. held the largest market share in 2025.
• Rising concerns regarding healthcare-associated infections and strict sterilization compliance requirements continue to drive demand.
• The country's well-established healthcare and pharmaceutical sectors remain key contributors to market expansion.

Asia Pacific Emerges as the Fastest-Growing Region

Asia Pacific is expected to register the highest CAGR during the forecast period.

Key growth drivers include:

• Expanding healthcare infrastructure
• Rising healthcare expenditures
• Growth in pharmaceutical manufacturing
• Increasing awareness of infection prevention
• Adoption of international sterilization standards

Rapid healthcare modernization across emerging economies is expected to create substantial opportunities for biological indicator manufacturers.

Market Size & Forecast

• Market Size (2025): USD 572.3 Million
• Estimated Market Size (2026): USD 613.6 Million
• Projected Market Size (2033): USD 1,106.2 Million
• CAGR (2026–2033): 8.8%
• Largest Regional Market: North America
• Fastest-Growing Region: Asia Pacific
• Leading Country Market: United States

Competitive Landscape

The biological indicators market remains highly fragmented, with both multinational corporations and regional manufacturers competing through innovation, quality improvements, and strategic expansion initiatives.

Key competitive strategies include:

• Product innovation and rapid-readout technologies
• Geographic expansion
• Strategic mergers and acquisitions
• Manufacturing capacity enhancement
• Regulatory compliance expertise
• Automation and digital sterilization monitoring solutions

As healthcare organizations increasingly focus on sterilization assurance and infection prevention, market participants continue investing in advanced biological indicator technologies to strengthen their competitive positions.

Explore Grand View Horizon to see global and regional level statistics related to the Biological Indicators Market

Key Biological Indicators Companies

The following companies are among the leading participants in the global biological indicators market:

• STERIS plc.
• Solventum
• Getinge
• Mesa Laboratories, Inc.
• 3M
• Terragene S.A.
• Propper Manufacturing Co., Inc.
• Tuttnauer
• Ecolab Inc.
• H.W. Andersen Products Ltd.
• MATACHANA GROUP
• LISTER BIOMEDICAL CO., LTD
• Liofilchem S.r.l.
• Steelco S.p.A
• Zhejiang Tailin Bioengineering Co., Ltd.
• Cole-Parmer Instrument Company, LLC (Antylia Scientific)
• Anhui Tianrun Medical Packaging Materials Co., Ltd.
• Medline Industries, LP.
• True Indicating

Conclusion

The global biological indicators market is poised for substantial growth, driven by increasing concerns over hospital-acquired infections, rising surgical volumes, stringent sterilization regulations, and expanding healthcare infrastructure worldwide. As biological indicators remain the most reliable method for validating sterilization effectiveness, their role in infection prevention and patient safety continues to strengthen across healthcare, pharmaceutical, and biotechnology sectors.

Technological advancements such as rapid-readout biological indicators, automation, and enhanced sterilization monitoring systems are improving operational efficiency and accelerating adoption. With regulatory compliance becoming increasingly critical and healthcare organizations prioritizing quality assurance, the biological indicators market is expected to experience sustained growth through 2033 and beyond.

Looking for a report customized to your requirements? Explore our Custom Research Offering

Grand View Research offers

• Focused market intelligence reports on specific geographies or high-growth segments
• Extended forecast timelines for long-term planning
• Competitor Benchmarking and Supply Chain Analysis
• Inclusion of regulatory and policy assessments
• Inclusion of custom data models, KPIs, or applications unique to your business
• Specific high-impact Data Decks and Tables to support effective decision making

And much more…